Physician profile
Benson Chin
NPI 1134218266
$14,701.35
in general payments reported to CMS, 2019-2025
57 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,893 · 2020: $2,078 · 2021: $2,346 · 2022: $2,277 · 2023: $2,627 · 2024: $1,716 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,848.39 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $2,045.65 | 2021-2025 | Ubrelvy, Vraylar, Creon |
| Astrazeneca Pharmaceuticals Lp | $1,110.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $876.66 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $603.04 | 2019-2021 | |
| Glaxosmithkline, LLC. | $601.89 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.25 | 2020-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.57 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $460.49 | 2019-2025 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $384.02 | 2020-2023 | Xarelto |
| Novo Nordisk INC | $368.34 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $367.69 | 2019-2023 | Korlym |
| Lilly USA, LLC | $366.03 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $300.34 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $263.92 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benson Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.